Sleepio to treat insomnia and insomnia symptoms (MTG70)
Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms
Search results
28 results
-
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults
-
Vaccine uptake in the general population (NG218)
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
-
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults
-
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)
Evidence-based recommendations on tucatinib (TUKYSA) for HER2 positive locally advanced or metastatic breast cancer in adults after 2 or more anti HER2 treatment therapies
-
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)
Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable
-
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults
-
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) (TA785)
NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission. We will review this decision if the company decides to make a submission
-
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults
-
myCOPD for managing chronic obstructive pulmonary disease (MTG68)
Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease
-
UroShield for preventing catheter-associated urinary tract infections (MTG69)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections
-
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults
-
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (TA782)
NICE is unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission
-
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)
Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children
-
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy
-
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
-
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor
-
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA774)
NICE is unable to make a recommendation on lenalidomide (Revlimid) for treating relapsed or refractory mantle cell lymphoma. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults
-
Dapagliflozin for treating chronic kidney disease (TA775)
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults
-
Prontosan for treating acute and chronic wounds (MTG67)
Evidence-based recommendations on Prontosan for treating acute and chronic wounds
-
3C Patch for treating diabetic foot ulcers (MTG66)
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers
-
Mental wellbeing at work (NG212)
This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.